Search - tctmd.com

Displaying 421 - 436 of 436

Sort: Relevancy | Date

Presentation TCT 2014

Systemic Therapies for the At-Risk Patient: From Darapladib to Anti-inflammatories and PCSK9 Inhibitors

Presenter: Valentin Fuster, Patrick W. Serruys, Harvey D. White

September 14, 2014

News Conference News TCT 2014

Experts Look to Big Data to Identify New Therapeutic Targets for CVD

September 14, 2014

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

August 28, 2014

News Industry News

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

August 25, 2014

News Industry News

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

July 30, 2014

News Industry News

The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions

May 01, 2014

News Industry News

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

News Industry News

Phase 3 Pivotal Data on Amgen's Novel Investigational Cholesterol-Lowering Medicine to be Featured at the American College of Cardiology's 63rd Annual Scientific Session

March 24, 2014

Presentation TCT 2013

PCSK9 Inhibitors: Too Good to Be True?

Presenter: Evan Stein

October 30, 2013

Presentation TCT 2012

PCSK9 Inhibitors: The Holy Grail?

Presenter: Evan Stein

October 23, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: STAMPEDE (Bariatric Surgery) and PCSK9 (LDL Reduction)

Presenter: Elizabeth Jackson

October 23, 2012

Video

» Interview

Beyond the Data: YELLOW III: PCSK9 Inhibitors and Plaque Characterization

March 5, 2023

Partner Content

COVID-19 TCTMD HUB

July 17, 2020

CME

Role of Interventional Cardiologists in Secondary Prevention of Acute Coronary Syndromes: Redefining Clinical Practice

Video

» On Record

On Record: The ODYSSEY Continues with PCSK9 Inhibitors

July 3, 2018

CME

Advertisement

Systemic Therapies for the At-Risk Patient: From Darapladib to Anti-inflammatories and PCSK9 Inhibitors

Experts Look to Big Data to Identify New Therapeutic Targets for CVD

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

Phase 3 Pivotal Data on Amgen's Novel Investigational Cholesterol-Lowering Medicine to be Featured at the American College of Cardiology's 63rd Annual Scientific Session

PCSK9 Inhibitors: Too Good to Be True?

PCSK9 Inhibitors: The Holy Grail?

Late Breaking Clinical Trials: STAMPEDE (Bariatric Surgery) and PCSK9 (LDL Reduction)

Beyond the Data: YELLOW III: PCSK9 Inhibitors and Plaque Characterization

COVID-19 TCTMD HUB

Role of Interventional Cardiologists in Secondary Prevention of Acute Coronary Syndromes: Redefining Clinical Practice

On Record: The ODYSSEY Continues with PCSK9 Inhibitors

Severe/Resistant Hypercholesterolemia: New Agents Redefining Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content